NCT05050474View on ClinicalTrials.gov

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 7, 2021

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions
COVID19
Interventions
BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Trial Locations (1)

511430

Guangdong Provincial Center for Disease Control and Prevention, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Guangdong Center for Disease Prevention and Control

OTHER_GOV

collaborator

Simoon Record Pharma Information Consulting Co., Ltd.

INDUSTRY

lead

Livzon Pharmaceutical Group Inc.

INDUSTRY